B-cell neoplasms differ widely in terms of their molecular and genetic features, tumour grade, aggressiveness, and cell-type, all of which can drastically alter disease course and subsequent treatment response. Healthcare professionals must take into consideration the heterogeneity of these tumours while deciding on the course of treatment. In this KOL commentary, Dr Jessica Okosun provides an overview on the biology of B-cell malignancies and highlights the importance of using the biological information to make informed therapeutic decisions to provide better treatment strategies.
Take Home Message